| DrugRepV_0802 | Cilostazol | Blood and Blood Forming Organs | Intermittent claudication | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (67.75 %) | Approved | 27476412 |
| DrugRepV_0865 | Prasugrel | Blood and Blood Forming Organs | Acute coronary syndrome | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (56.09 %) | Approved | 27476412 |
| DrugRepV_0883 | Eptifibatide | Blood and Blood Forming Organs | Myocardial infarction | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (54.02 %) | Approved | 27476412 |
| DrugRepV_0904 | Clopidogrel Hydrogen Sulfate | Blood and Blood Forming Organs | Myocardial infarction | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (57.555 %) | Approved | 27476412 |
| DrugRepV_0979 | Ticlopidine Hydrochloride | Blood and Blood Forming Organs | Stroke | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (55.53 %) | Approved | 27476412 |
| DrugRepV_0984 | Warfarin Sodium | Blood and Blood Forming Organs | Coagulation disorders | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (48.055 %) | Approved | 27476412 |
| DrugRepV_1052 | Dipyridamole | Blood and Blood Forming Organs | Coagulation disorders | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.91 %) | Approved | 27476412 |
| DrugRepV_1147 | Tirofiban Hydrochloride | Blood and Blood Forming Organs | Acute coronary syndrome | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (43.245 %) | Approved | 27476412 |
| DrugRepV_1246 | Tranexamic Acid | Blood and Blood Forming Organs | Hemorrhage | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.975 %) | Approved | 27476412 |
| DrugRepV_1286 | Hydroxocobalamin Hydrochloride | Blood and Blood Forming Organs | Vitamin B12 deficiency | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (45.41 %) | Approved | 27476412 |
| DrugRepV_1292 | Argatroban | Blood and Blood Forming Organs | Coagulation disorders | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.59 %) | Approved | 27476412 |
| DrugRepV_1497 | Aminocaproic Acid | Blood and Blood Forming Organs | Antifibrinolytic agent | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (37.285 %) | Approved | 27476412 |
| DrugRepV_1619 | Warfarin | Blood and Blood Forming Organs | Coagulation disorders | Influenza virus | A/Anhui/01/2013 |  | Transcriptomic response-DEG | Decrease | Approved | 24991006 |
| DrugRepV_1631 | Eptifibatide | Blood and Blood Forming Organs | Myocardial infarction | Influenza virus | A/Anhui/01/2013 | | Transcriptomic response-DEG | Decrease | Approved | 24991006 |
| DrugRepV_1651 | Hydroxocobalamin | Blood and Blood Forming Organs | Vitamin B12 deficiency | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1664 | Indobufen | Blood and Blood Forming Organs | Atrial Fibrillation | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1669 | Vitamin B12 | Blood and Blood Forming Organs | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1722 | Hydroxocobalamin | Blood and Blood Forming Organs | Vitamin B12 deficiency | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1735 | Indobufen | Blood and Blood Forming Organs | Atrial Fibrillation | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1740 | Vitamin B12 | Blood and Blood Forming Organs | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1793 | Hydroxocobalamin | Blood and Blood Forming Organs | Vitamin B12 deficiency | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1806 | Indobufen | Blood and Blood Forming Organs | Atrial Fibrillation | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1811 | Vitamin B12 | Blood and Blood Forming Organs | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_2164 | Menadione | Blood and Blood Forming Organs | Blood clotting | Bone calcification | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Decrease (54.2699321 %) | Approved, Nutraceutical | 27742486 |
| DrugRepV_2208 | Dipyridamole | Blood and Blood Forming Organs | Coagulation disorders | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.91414617 %) | Approved | 27742486 |
| DrugRepV_2350 | Tranexamic Acid | Blood and Blood Forming Organs | Hemorrhage | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.23343185 %) | Approved | 27742486 |
| DrugRepV_2390 | Argatroban | Blood and Blood Forming Organs | Coagulation disorders | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.35584553 %) | Approved | 27742486 |
| DrugRepV_2507 | L-Arginine Hydrochloride | Blood and Blood Forming Organs | Nutritional supplementation | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.02074722 %) | Investigational, Nutraceutical | 27742486 |
| DrugRepV_2514 | Phenindione | Blood and Blood Forming Organs | Cardiomyopathy, atrial fibrillation | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.0791815 %) | Approved, Investigational | 27742486 |
| DrugRepV_2574 | BIBR-1048 | Blood and Blood Forming Organs | Thrombosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.2578913 %) | Approved | 27742486 |
| DrugRepV_2594 | Vitamin B12 | Blood and Blood Forming Organs | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.5062413 %) | Approved | 27742486 |
| DrugRepV_2622 | Cilostazol | Blood and Blood Forming Organs | Intermittent claudication | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.8044261 %) | Approved | 27742486 |
| DrugRepV_2634 | Clopidogrel | Blood and Blood Forming Organs | Myocardial infarction | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.943957 %) | Approved | 27742486 |
| DrugRepV_2717 | Prasugrel | Blood and Blood Forming Organs | Acute coronary syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.2301485 %) | Approved | 27742486 |
| DrugRepV_2769 | Triflusal | Blood and Blood Forming Organs | Thromboembolic disorders | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.3917465 %) | Approved, Investigational | 27742486 |
| DrugRepV_2866 | Carbazochrome Sodium Sulfonate | Blood and Blood Forming Organs | Hemorrhage | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-7.3048436 %) | Experimental | 27742486 |
| DrugRepV_2908 | Aminocaproic Acid | Blood and Blood Forming Organs | Antifibrinolytic agent | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-9.6373425 %) | Approved | 27742486 |
| DrugRepV_3113 | Menadione | Blood and Blood Forming Organs | Blood clotting | Bone calcification | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (97.53 %) | Approved, Nutraceutical | 23275491 |
| DrugRepV_3161 | Dextran Sulphate | Blood and Blood Forming Organs | NA | Chikungunya virus | Ross C347 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 14670584 |
| DrugRepV_5589 | Camostat | Blood and Blood Forming Organs | Pancreatitis | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Experimental | 32353859 |
| DrugRepV_5824 | Dicoumarol | Blood and Blood Forming Organs | Coagulation disorders | Dengue virus | NA | | Immunoflourescence assay | Decrease (45.99 %) | Approved | 22155902 |
| DrugRepV_6225 | Heparin | Blood and Blood Forming Organs | Venous thrombosis | Dengue virus | NGC | | Plaque assay | Decrease (50 %) | Approved, Investigational | 24583230 |
| DrugRepV_6256 | Heparin | Blood and Blood Forming Organs | Venous thrombosis | Dengue virus | D1/Lao/03 | | Focus forming assay | Decrease (50 %) | Approved, Investigational | 20851716 |
| DrugRepV_6257 | Heparin | Blood and Blood Forming Organs | Venous thrombosis | Dengue virus | ThNH-7/93 | | Focus forming assay | Decrease (50 %) | Approved, Investigational | 20851716 |
| DrugRepV_6258 | Heparin | Blood and Blood Forming Organs | Venous thrombosis | Dengue virus | D3/BDH02-01 | | Focus forming assay | Decrease (50 %) | Approved, Investigational | 20851716 |
| DrugRepV_6259 | Heparin | Blood and Blood Forming Organs | Venous thrombosis | Dengue virus | ThD 17/97 | | Focus forming assay | Decrease (50 %) | Approved, Investigational | 20851716 |
| DrugRepV_6263 | Dextran Sulphate | Blood and Blood Forming Organs | Antithrombotic | Dengue virus | New Guinea C (NGC) | | Flow cytometry | Decrease (50 %) | Phase I | 19264337 |
| DrugRepV_6268 | Dextran Sulphate | Blood and Blood Forming Organs | Antithrombotic | Dengue virus | New Guinea C (NGC) | | RT-PCR | Decrease (50 %) | Phase I | 19264337 |
| DrugRepV_6273 | Dextran Sulphate | Blood and Blood Forming Organs | Antithrombotic | Dengue virus | New Guinea C (NGC) | | Flow cytometry | Decrease (50 %) | Phase I | 19264337 |
| DrugRepV_6278 | Dextran Sulphate | Blood and Blood Forming Organs | Antithrombotic | Dengue virus | New Guinea C (NGC) | | RT-PCR | Decrease (50 %) | Phase I | 19264337 |
| DrugRepV_6282 | Heparin | Blood and Blood Forming Organs | Venous thrombosis | Dengue virus | NGC | | Virus yield reduction assay | Decrease (50 %) | Approved, Investigational | 15911027 |
| DrugRepV_6286 | Heparin | Blood and Blood Forming Organs | Venous thrombosis | Dengue virus | NGC | | Virus yield reduction assay | Decrease (50 %) | Approved, Investigational | 15911027 |
| DrugRepV_6290 | Heparin | Blood and Blood Forming Organs | Venous thrombosis | Dengue virus | NGC | | Virus yield reduction assay | Decrease (50 %) | Approved, Investigational | 15911027 |
| DrugRepV_6294 | Heparin | Blood and Blood Forming Organs | Venous thrombosis | Dengue virus | NGC | | Virus yield reduction assay | Decrease (50 %) | Approved, Investigational | 15911027 |
| DrugRepV_6298 | Heparin | Blood and Blood Forming Organs | Venous thrombosis | Dengue virus | H87 | | Virus yield reduction assay | Decrease (50 %) | Approved, Investigational | 15911027 |
| DrugRepV_6302 | Heparin | Blood and Blood Forming Organs | Venous thrombosis | Dengue virus | H87 | | Virus yield reduction assay | Decrease (50 %) | Approved, Investigational | 15911027 |
| DrugRepV_6306 | Heparin | Blood and Blood Forming Organs | Venous thrombosis | Dengue virus | H87 | | Virus yield reduction assay | Decrease (50 %) | Approved, Investigational | 15911027 |
| DrugRepV_6310 | Heparin | Blood and Blood Forming Organs | Venous thrombosis | Dengue virus | H87 | | Virus yield reduction assay | Decrease (50 %) | Approved, Investigational | 15911027 |
| DrugRepV_6312 | Heparin | Blood and Blood Forming Organs | Venous thrombosis | Dengue virus | NGC | | Flow cytometry | Decrease (86 %) | Approved, Investigational | 16309754 |
| DrugRepV_6337 | Dicoumarol | Blood and Blood Forming Organs | Coagulation disorders | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (45.99 %) | Approved | 22155902 |
| DrugRepV_7261 | Heparin | Blood and Blood Forming Organs | Venous thrombosis | Japanese encephalitis virus | JaOArS982 | | Focus forming assay | Decrease (50 %) | Approved, Investigational | 20851716 |
| DrugRepV_7262 | Heparin | Blood and Blood Forming Organs | Venous thrombosis | Japanese encephalitis virus | Nakayama | | Flow cytometry | Decrease (70 %) | Approved, Investigational | 16309754 |
| DrugRepV_7604 | Eltrombopag | Blood and Blood Forming Organs | Idiopathic thrombocytopenic purpura (ITP) | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7605 | Eltrombopag | Blood and Blood Forming Organs | Idiopathic thrombocytopenic purpura (ITP) | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7610 | Camostat | Blood and Blood Forming Organs | Pancreatitis | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Experimental | 32438446 |
| DrugRepV_7699 | Enoxaparin | Blood And Blood Forming Organs | Deep vein thrombosis | SARS Coronavirus-2 | | NA | NA | Decrease (50 %) | Approved | 32577638 |
| DrugRepV_8336 | Camostat | Blood And Blood Forming Organs | Chronic pancreatitis | SARS Coronavirus-2 | NA | NA | NA | Decrease (50 %) | Experimental | 32596694 |